Supporting Universal Hepatitis B Birth-Dose Vaccination

As the leading organization representing hepatology clinicians and researchers, AASLD is committed to advancing evidence-based policies that protect liver health. Vaccination against hepatitis B at birth is one of the most effective tools we have to prevent lifelong infection and reduce liver disease.

The CDC’s universal hepatitis B birth-dose recommendation is a proven public health success. Since its adoption in 1991, infant hepatitis B infections in the U.S. have declined by 95%, and more than 90,000 deaths have been prevented, ranking this vaccine among the most impactful childhood immunizations. A recent study also found that hepatitis B vaccination has prevented over 6 million infections and nearly 1 million hospitalizations in less than 30 years. The impact is clear.

Upcoming! WIC Webinar - Building Executive Presence

Want to lead with vision and confidence? Participate in the first webinar of a three-part series: Lessons Beyond Medicine: Curating your Career. On Tuesday, Sept. 9, join Heidi Dieter, Chief Research Administrator at Mayo Clinic, for an exclusive webinar hosted by the Women's Initiative Committee. Heidi will share real stories, tips, and tricks for making bold decisions and driving success at the highest levels.

New! Practice Guideline on Graft Complications in Adult Liver Transplantation

Discover the latest evidence-based recommendations for managing post-transplant challenges including graft rejection, recurrent disease, and immunosuppression. This essential guideline empowers hepatology professionals and transplant care teams with an evidence-based roadmap to optimize post-transplant care and improve patient outcomes.